In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
US generics drugmaker Mylan has confirmed that it has been sued by German pharma major Bayer and partner Onyx Pharmaceuticals (a subsidiary of Amgen), in connection with the filing of an Abbreviated New Drug Application with the US Food and Drug Administration for sorafenib. 10 February 2015
The Scottish Medicines Consortium has decided to recommend Abraxane (paclitaxel) in combination with gemcitabine for the treatment of metastatic adenocarcinoma of the pancreas. 10 February 2015
Janssen, a UK-based subsidiary of US health care giant Johnson & Johnson is disappointed with the Scottish Medicines Consortium (SMC) decision published today, which does not recommend the use of Zytiga (abiraterone acetate). 9 February 2015
US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International NV (Janssen) has received approval from the European Commission for a variation to the terms of the marketing authorization of Velcade (bortezomib). 6 February 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has completed its examination of Latuda (lurasidone) as to whether this new drug offers an added benefit over the appropriate comparator therapy. 6 February 2015
UK pharma major GlaxoSmithKline has announced positive overall survival rates from the Phase III study of Tafinlar (dabrafenib) and Mekinist (trametinib) in combination. 6 February 2015
At the Symposium on the Application of Genetic Testing in Individualized Diagnosis and Treatment of Tumor recently held in Tianjin, China, the research team led by Hao Jihui of the Pancreas Oncology Department of Tianjin Medical University Cancer Hospital announced that they had achieved a major breakthrough in the field of nano-carrier drugs for pancreatic cancer. 6 February 2015
A study by the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust has shown abiraterone significantly extends the lives of patients with advanced prostate cancer, if given before chemotherapy. 5 February 2015
The market value for therapeutics to treat HER2-negative breast cancer will increase more than fourfold between 2013 and 2023, says market research company GlobalData. 5 February 2015
The US Food and Drug Administration yesterday granted accelerated approval for pharma giant Pfizer’s Ibrance (palbociclib) to treat advanced (metastatic) breast cancer, making this the first-ever marketing clearance for the drug. 4 February 2015
Swiss drug major Roche has announced positive results from the Phase III study of Gazyva (obintuzumab) in indolent non-Hodgkin’s lymphoma. 4 February 2015
The Japanese unit of Swiss drug major Novartis is facing suspension following allegations of data manipulation in the results of Diovan (valsartan) clinical trials. 4 February 2015
Today marks World Cancer Day, which this year focuses on “achieving treatment for all.” However, in less than five weeks’ time, men with hormone resistant advanced prostate cancer in England who could benefit from Jevtana (cabazitaxel) will not be able to access it. 4 February 2015
Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos Stendhal for NEPA, an oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). 2 February 2015
The US Food and Drug Administration has granted Breakthrough Therapy Designation for MPDL3280A (anti-PDL1) in non-small cell lung cancer, developed by Swiss drug major Roche. 2 February 2015
US biotech firm Dendreon says it has reached an agreement with Canada’s Valeant Pharmaceuticals International whereby, subject to bankruptcy court approval, Valeant will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process. 30 January 2015
The Asia-Pacific (APAC) therapeutics market for ovarian cancer (OC) will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, expanding at a compound annual growth rate (CAGR) of 5.1%. 30 January 2015
US biotech firm Celgene posted 2014 financials before the markets opened this morning, showing that fourth quarter net product sales were $2.055 billion, an increase of 19%. 29 January 2015
UK pharma major GlaxoSmithKline has received clearance from the European Commission for its proposed three-part transaction with Swiss drug major Novartis. 29 January 2015